MEDICAMEQ · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 33/100 — Quality 36 · Valuation 50 · Momentum 0
| Share price | ₹236.50 |
| Market cap | ₹333 Cr |
| P/E ratio | 34.0 |
| P/B ratio | 1.0 |
| ROE | 71.1% |
| ROCE | 5.4% |
| Dividend yield | 0.41% |
| Book value | ₹234.32 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹198 Cr | ₹10 Cr | 10.0% |
| 2025 | ₹163 Cr | ₹7 Cr | 9.0% |
| 2024 | ₹179 Cr | ₹9 Cr | 13.0% |
| 2023 | ₹141 Cr | ₹15 Cr | 17.0% |
| 2022 | ₹115 Cr | ₹15 Cr | 21.0% |
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.